Economic burden of psoriatic arthritis
Economic burden of psoriatic arthritis
复制标题
DOI：
10.2165/00019053-200826020-00003
复制
发表时间：
2008-01-01
影响因子：
4.4
通讯作者：
Kavanaugh, Arthur
中科院分区：
文献类型：
--
作者：
Ackermann, Christoph;Kavanaugh, Arthur
银屑病性关节炎（Psoriatic arthritis，PsA）是一种慢性自身免疫性疾病，其特征是与皮肤银屑病（Psoriasis，Ps）相关的炎性关节炎。PsA可能表现出异质性和可变的临床过程，涉及外周和轴向关节，关节周围结构，如附着点，以及皮肤和指甲。越来越多的证据表明，受影响的患者可能有显着的影像学关节损伤，功能障碍，生活质量（QOL）下降和长期工作能力丧失。PsA的经济负担可能是相当大的。PsA的药物经济学评价越来越受到关注，主要是由于引入了高效但昂贵的生物制剂，特别是促炎细胞因子肿瘤坏死因子（TNF）-α的抑制剂。用TNF α抑制剂治疗不仅导致关节炎的体征和症状的实质性改善，而且还导致疾病的所有不同部位的改善，例如轴性关节炎、趾炎、附着点炎和皮肤病。TNFa抑制剂的显著临床疗效需要考虑到对其价值的全面评估中。需要进一步分析以优化新生物制剂在PsA中的使用。
Psoriatic arthritis (PsA) is a chronic autoimmune disease characterized by inflammatory arthritis in association with skin psoriasis (Ps). PsA may show a heterogeneous and variable clinical course, with involvement of peripheral and axial diarthrodial joints, periarticular structures such as entheses, as well as the skin and nails. Evidence is increasing that affected patients can have significant radiographic joint damage, functional impairment, reduced quality of life (QOL) and long-term work disability. The economic burden of PsA can be considerable.There is an increasing interest in pharmacoeconomic evaluations in PsA, driven mostly by the introduction of highly effective but expensive biologic agents, particularly inhibitors of the proinflammatory cytokine tumour necrosis factor (TNF)-alpha. Treatment with TNF alpha inhibitors results in not only substantial improvements in signs and symptoms of arthritis, but also improvements in all distinct sites of the disease, such as axial arthritis, dactylitis, enthesitis and skin disease.There is a dearth of published pharmacoeconomic evaluations in the field of PsA. The notable clinical efficacy of the TNFa inhibitors needs to be factored into a comprehensive assessment of their value. Further analyses are needed to optimize the use of the new biologic agents in PsA.